サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1771312

創薬プラットフォーム市場：業界動向と世界の予測 - ディスプレイライブラリ技術タイプ別、分子タイプ別、主要地域別

Drug Discovery Platforms Market: Industry Trends and Global Forecasts - Distribution by Type of Display Library Technology, Type of Molecule and Key Geographical Regions

出版日
ページ情報
英文 220 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
創薬プラットフォーム市場：業界動向と世界の予測 - ディスプレイライブラリ技術タイプ別、分子タイプ別、主要地域別
出版日: 2025年07月15日
発行: Roots Analysis
ページ情報: 英文 220 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の創薬プラットフォーム市場：概要

世界の創薬プラットフォームの市場規模は、今年1億3,900万米ドルとなりました。同市場は、予測期間中に13.4%のCAGRで拡大すると予測されています。

市場セグメンテーションと機会分析は、以下のパラメータでセグメント化されています：

ディスプレイライブラリ技術タイプ

  • ファージディスプレイ
  • 酵母ディスプレイ
  • その他

分子タイプ別

  • 抗体
  • ペプチド
  • その他

主な地域

  • 北米
  • 欧州
  • アジア太平洋

世界の創薬プラットフォーム市場：成長と動向

創薬は常に時間のかかるプロセスです。実際、医薬品を商業的に発売するまでには、平均で10～15年の歳月と40～100億米ドル相当の投資が必要です。創薬のプロセスには、ターゲットの選択と検証、ヒット化合物の創出、リード化合物の最適化、プロトコルの特性評価など、様々なステップが含まれます。これらのステップのうち、ヒット（有効性が確認された生物学的標的に対する潜在的な医薬品候補）の創出は、極めて資源集約的なプロセスです。バリデートされたターゲットに対するヒット化合物の創出には、平均して約18ヶ月が費やされることは特筆に値します。これに加えて、創薬のヒット生成からリード化合物同定の段階では、約25％の確率で失敗します。このような懸念に対処するため、開発者は従来の手法から新規の創薬プラットフォームの使用に重点を移しつつあります。

Drug Discovery Platforms Market-IMG1

長年にわたり、実行可能な治療リードを生み出すための数多くの手法やアプローチが確立されてきました。ハイブリドーマ技術、B細胞クローニング、トランスジェニック動物ベースの技術、in vitroディスプレイ法、哺乳類、酵母、細菌細胞を含む細胞表面ディスプレイ技術などです。現代の医学研究において、ディスプレイライブラリは、さまざまな新規治療薬の生成に効果的に利用されており、従来の薬剤スクリーニング法に比べていくつかの利点があります。これらの利点には、大規模なハイスループット・スクリーニングを可能にすること、実行可能なリード化合物を同定する際に多様性をもたらすこと、このアプローチによって発見された薬理学的候補化合物に対する免疫反応のリスクを低減することなどが含まれます。ディスプレイ技術は徐々に、創薬プロセスにおける大きな進歩を促してきました。その結果、創薬プラットフォーム市場は予測期間中に力強い成長を遂げると予想されます。

世界の創薬プラットフォーム市場：主要インサイト

当レポートでは、世界の創薬プラットフォーム市場の現状を調査し、潜在的な成長機会を特定しています。当レポートの主な調査結果は以下の通りです。

  • 世界のさまざまな地域に拠点を置く複数の企業が、独自のディスプレイライブラリ技術を有し、さまざまなタイプの薬理学的分子の探索のための提携サービスを提供していると主張しています。
  • ファージディスプレイ（～70％）は、最も成功したディスプレイ技術のひとつと考えられています。利害関係者は、酵母や哺乳類細胞をベースにしたものなど、他の類似アプローチもいくつか研究しています。
  • ディスプレイ技術には、大規模生産、配列への直接アクセス、多様なクローンのスクリーニングの容易さなど、いくつかの利点があります。
  • ディスプレイライブラリは、固定化抗原に対する抗体のin vitro選択や、免疫原性の低い標的に対する抗体の単離に用いることができます。
  • 薬剤候補を生み出すために、動物の免疫系の制御下で操作できる複数の動物モデルを選択に用いる参入企業もいます。
  • この分野への関心が高まっていることは、提携活動の活発化からも明らかです。事実、過去2年間で、さまざまなタイプのディスプレイライブラリ技術を含む提携が最大数結ばれています。
Drug Discovery Platforms Market-IMG2
  • 既存企業も新興企業も複数のパートナーシップを結んでおり、そのほとんどは研究や治療目的で使用できる技術のライセンス契約（～45％）です。
  • 様々なタイプのin vitroディスプレイライブラリとそれを可能にする技術、そして創薬・治療法におけるそれらの使用法を説明するアプローチに関連する科学的文献の出版が顕著に増加しています。
  • 過去2年間で、ディスプレイライブラリ技術と創薬への応用に焦点を当てた研究論文を含む出版物の数は急激に増加しています。
  • 様々な論文が、in-vitroディスプレイ技術や、膨大な分子の単離のための大規模ライブラリの使用に焦点を当てています。さらに、これらの技術は主に治療や診断用途に使用する有望なリード候補を同定することを目的としています。
  • ファージディスプレイ以外にも、酵母ディスプレイや細胞表面ディスプレイなどのディスプレイ技術も、様々な治療用分子の生成のために研究されています。
  • ディスプレイライブラリに関連する知的財産も急増しており、これらの技術に関連する数多くの特許（～30,000件の特許出願）が世界中のいくつかの組織に出願され、付与されています。
  • 最近出願された特許の数が多いにもかかわらず（したがって特許の残存期間が長い）、相対的な評価が最も高い特許は全体のわずか0.21％です。
  • 特に、ファージディスプレイアプローチは、多くの承認薬の発見に広く使われています。事実、市場で最も売れている生物製剤のひとつであるヒュミラ（R）は、同じ技術を用いて発見されました。
  • 市場は年率13.4%で成長すると予測されています。予測される機会は、さまざまなディスプレイ技術、分子タイプ別、主要な地理的地域に分散していると思われます。
Drug Discovery Platforms Market-IMG3

創薬プラットフォーム市場の参入企業例

  • Abzena
  • Creative Biolabs
  • Distributed Bio（Subsidiary of Charles River）
  • ImmunoPrecise Antibodies
  • IONTAS
  • LakePharma
  • Leading Biology
  • Sino Biological
  • XOMA

当レポートでは、世界の創薬プラットフォーム市場について調査し、市場の概要とともに、ディスプレイライブラリ技術タイプ別、分子タイプ別動向、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 章の概要
  • ディスプレイライブラリ技術の概要
  • ディスプレイライブラリの種類
  • ディスプレイライブラリのアプリケーション
  • 将来の展望

第4章 市場情勢：ライブラリベースディスプレイ技術とサービス（ファージディスプレイ）

  • 章の概要
  • ディスプレイライブラリ技術と関連サービス（ファージディスプレイ）：市場情勢
  • ディスプレイライブラリ技術と関連サービス（ファージディスプレイ）：主要業界参入企業

第5章 市場情勢：ディスプレイライブラリ技術と関連サービス（その他のディスプレイ技術）

  • 章の概要
  • ディスプレイライブラリ技術と関連サービス（その他のディスプレイ技術）：市場情勢
  • ディスプレイライブラリ技術と関連サービス（その他のディスプレイ技術）：主要業界参入企業

第6章 企業プロファイル

  • 章の概要
  • Abzena
  • Creative Biolabs
  • Distributed Bio（Subsidiary of Charles River）
  • ImmunoPrecise Antibodies
  • IONTAS
  • LakePharma
  • Leading Biology
  • Sino Biological
  • XOMA

第7章 ケーススタディ：ファージディスプレイ法を用いて発見された生物製剤

  • 章の概要
  • ファージディスプレイ法を用いて発見された生物製剤
  • ファージディスプレイ法を用いて発見された生物製剤：概要
    • ヒュミラ（R）（アダリムマブ）
    • トレムフィア（R）（グセルクマブ）
    • タクザイロ（R）（ラナデルマブ）
    • シンサ（R）
    • ポートラッザ（TM）（ネシツムマブ）
  • 結論

第8章 パートナーシップとコラボレーション

  • 章の概要
  • パートナーシップモデル
  • ディスプレイライブラリ技術と関連サービス：最近のパートナーシップとコラボレーション

第9章 出版物の分析

第10章 特許分析

  • 章の概要
  • 範囲と調査手法
  • ディスプレイライブラリ技術：特許分析

第11章 市場規模の評価と機会分析

  • 章の概要
  • 主な前提と予測調査手法
  • 世界のディスプレイライブラリ技術市場（ヒット生成サービス）（2035年まで）
  • ディスプレイライブラリ技術と関連サービス市場（2035年まで）：ディスプレイライブラリ技術タイプ別
  • ディスプレイライブラリ技術と関連サービス市場（2035年まで）：分子タイプ別
  • ディスプレイライブラリ技術と関連サービス市場（2035年まで）：地域別

第12章 結論

第13章 エグゼクティブ洞察

第14章 付録1：表形式データ

第15章 付録2：企業・団体一覧

図表

List of Tables

  • Figure 3.1. Popular Display Library Technologies
  • Figure 3.2. Structure of a Bacteriophage
  • Figure 3.3. Phage Display Technique: Basic Steps
  • Figure 3.4. Construction of mRNA Display Technology
  • Figure 3.5. Construction of Bacterial Display Library
  • Figure 4.1. Phage Display Library Technologies and Affiliated Services: Type of Molecule Discovered
  • Figure 4.2. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
  • Figure 4.3. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Library
  • Figure 4.4. Phage Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
  • Figure 4.5. Phage Display Library Technologies and Affiliated Services: Distribution by Source Organism
  • Figure 4.6. Phage Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
  • Figure 4.7. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
  • Figure 4.8. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
  • Figure 4.9. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
  • Figure 4.10. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
  • Figure 5.1. Other Display Library Technologies and Affiliated Services: Distribution by Type of Molecule Discovered
  • Figure 5.2. Other Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
  • Figure 5.3. Other Display Library Technologies and Affiliated Services: Distribution by Type of Library
  • Figure 5.4. Other Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
  • Figure 5.5. Other Display Library Technologies and Affiliated Services: Distribution by Source Organism
  • Figure 5.6. Other Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
  • Figure 5.7. Other Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
  • Figure 5.8. Other Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
  • Figure 5.9. Other Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
  • Figure 5.10. Other Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
  • Figure 6.1. Creative Biolabs: Service Portfolio
  • Figure 6.2. ImmunoPrecise Antibodies: Service Portfolio
  • Figure 6.3. IONTAS: Service Portfolio
  • Figure 6.4. LakePharma: Service Portfolio
  • Figure 6.5. Leading Biology: Service Portfolio
  • Figure 6.6. Leading Biology: Premade Phage Display Antibody Libraries
  • Figure 6.7. Sino Biological: Service Portfolio
  • Figure 7.1. Biologics Discovered Using Phage Display Method: First Launch Timeline
  • Figure 7.2. Biologics Discovered Using Phage Display Method: Word Cloud Representation of Target Antigen / Gene
  • Figure 7.3. Biologics Discovered Using Phage Display Method: Distribution by Target Disease Indications and Therapeutic Area
  • Figure 7.4. Biologics Discovered Using Phage Display Method: Logo Landscape Highlighting Revenues Generated in 2020
  • Figure 8.1. Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3. Partnerships and Collaborations: Distribution by Focus Area (Type of Molecule)
  • Figure 8.4. Partnerships and Collaborations: Distribution by Focus Area (Target Therapeutic Area)
  • Figure 8.5. Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 8.6. Most Active Players: Distribution by Number of Partnerships
  • Figure 8.7. Partnerships and Collaborations: Distribution by Geography
  • Figure 8.8. Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Figure 9.1. Publication Analysis: Cumulative Year-wise Trend, Since 2017
  • Figure 9.2. Publication Analysis: Distribution by Focus Area
  • Figure 9.3. Publication Analysis: Distribution by Type of Molecule
  • Figure 9.4. Publication Analysis: Word Cloud of Study Titles
  • Figure 9.5. Key Journals: Distribution by Number of Publications
  • Figure 10.1. Patent Analysis: Distribution by Type of Patent
  • Figure 10.2. Patent Analysis: Cumulative Distribution by Publication Year, Since 2017
  • Figure 10.3. Patent Analysis: Distribution by Type of Patent and Publication Year
  • Figure 10.4. Patent Analysis: Distribution by Geography
  • Figure 10.5. Patent Analysis: Distribution by Jurisdiction
  • Figure 10.6. Patent Analysis: Distribution by CPC Symbols
  • Figure 10.7. Patent Analysis: Emerging Focus Areas
  • Figure 10.8. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 10.9. Leading Industry Players: Distribution by Number of Patents
  • Figure 10.10. Leading Players: Distribution by International Patents
  • Figure 10.11. Patent Analysis: Distribution of Patents by Age
  • Figure 10.12. Patent Analysis: Distribution of Patents by Geography, Since 2017
  • Figure 10.13. Display Library Technologies: Patent Valuation
  • Figure 11.1. Global Display Library Technologies and Affiliated Services Market (Focus on Hit Generation Services), Till 2035 (USD Million)
  • Figure 11.2. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Display Library Technology (USD Million)
  • Figure 11.3. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Molecule (USD Million)
  • Figure 11.4. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Geography (USD Million)
  • Figure 11.5. Display Library Technologies and Affiliated Services Market in North America, Till 2035 (USD Million)
  • Figure 11.6. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Phage Display Technology (USD Million)
  • Figure 11.7. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Yeast Display Technology (USD Million)
  • Figure 11.8. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Display Technologies (USD Million)
  • Figure 11.9. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Antibodies (USD Million)
  • Figure 11.10. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Peptides (USD Million)
  • Figure 11.11. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Molecules (USD Million)
  • Figure 11.12. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Phage Display Technology (USD Million)
  • Figure 11.13. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Yeast Display Technology (USD Million)
  • Figure 11.14. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Display Technologies (USD Million)
  • Figure 11.15. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Antibodies (USD Million)
  • Figure 11.16. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Peptides (USD Million)
  • Figure 11.17. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Molecules (USD Million)
  • Figure 11.18. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Phage Display Technology (USD Million)
  • Figure 11.19. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Yeast Display Technology (USD Million)
  • Figure 11.20. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Display Technologies (USD Million)
  • Figure 11.21. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Antibodies (USD Million)
  • Figure 11.22. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Peptides (USD Million)
  • Figure 11.23. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Molecules (USD Million)

List of Figures

  • Table 4.1. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Developers, Type of Molecule Generated and Types of Antibodies Generated
  • Table 4.2. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Type of Library and Library Size / Complexity
  • Table 4.3. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Animal Model Use
  • Table 4.4. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Information on Types of Services Offered
  • Table 4.5. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): Companies Offering Drug Discovery Platform(s)
  • Table 4.6. Display Library Technologies and Affiliated Services Market Landscape (Focus on Phage Display): List of Companies
  • Table 5.1. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Developer, Type of Molecule Generated and Type of Antibodies Generated
  • Table 5.2. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Type of Library and Library Size / Complexity
  • Table 5.3. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Animal Model Used
  • Table 5.4. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Information on Types of Services Offered
  • Table 5.5. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): Companies Offering Drug Discovery Platform(s)
  • Table 4.6. Display Library Technologies and Affiliated Services Market Landscape (Focus on Other Display Technologies): List of Companies
  • Table 6.1. Display Library Technologies and Affiliated Services: List of Companies Profiled
  • Table 6.2. Abzena: Company Snapshot
  • Table 6.3. Abzena: Recent Developments and Future Outlook
  • Table 6.4. Creative Biolabs: Company Snapshot
  • Table 6.5. Creative Biolabs: Recent Developments and Future Outlook
  • Table 6.6. Distributed Bio: Company Snapshot
  • Table 6.6. Distributed Bio: Recent Developments and Future Outlook
  • Table 6.7. ImmunoPrecise Antibodies: Company Snapshot
  • Table 6.8. ImmunoPrecise Antibodies: Recent Developments and Future Outlook
  • Table 6.9. IONTAS: Company Snapshot
  • Table 6.10. IONTAS: Recent Developments and Future Outlook
  • Table 6.11. LakePharma: Company Snapshot
  • Table 6.12. LakePharma: Recent Developments and Future Outlook
  • Table 6.13. Leading Biology: Company Snapshot
  • Table 6.14. Sino Biological: Company Snapshot
  • Table 6.16. XOMA: Company Snapshot
  • Table 6.17. XOMA: Recent Developments and Future Outlook
  • Table 7.1. List of Approved Biologics Discovered Using Phage Display Method: Information on Launch Year, Target, Indication and Therapeutic Area
  • Table 7.2. List of Clinical Stage Biologics Discovered Using Phage Display Library Method
  • Table 8.1. Partnerships and Collaborations: Information on Year and Type, Since 2017
  • Table 8.2. Partnerships and Collaborations: Information on Focus Area
  • Table 8.3. Partnerships and Collaborations: Information on Geography
  • Table 10.1. Display Library Technologies: Prominent CPC Codes
  • Table 10.2. Display Library Technologies: Most Popular CPC Symbols
  • Table 10.3. Display Library Technologies: List of Top CPC Symbols
  • Table 10.4. Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
  • Table 10.5. Patent Analysis: List of Relatively High Value Patents
  • Table 14.1. Phage Display Library Technologies and Affiliated Services: Type of Molecule Discovered
  • Table 14.2. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
  • Table 14.3. Phage Display Library Technologies and Affiliated Services: Distribution by Type of Library
  • Table 14.4. Phage Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
  • Table 14.5. Phage Display Library Technologies and Affiliated Services: Distribution by Animal Model Used
  • Table 14.6. Phage Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
  • Table 14.7. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
  • Table 14.8. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
  • Table 14.9. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
  • Table 14.10. Phage Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
  • Table 14.11. Other Display Library Technologies and Affiliated Services: Distribution by Type of Molecules Generated
  • Table 14.12. Other Display Library Technologies and Affiliated Services: Distribution by Type of Antibodies Generated
  • Table 14.14. Other Display Library Technologies and Affiliated Services: Distribution by Type of Library
  • Table 14.14. Other Display Library Technologies and Affiliated Services: Distribution by Library Size / Complexity
  • Table 14.15. Other Display Library Technologies and Affiliated Services: Distribution by Animal Model Used
  • Table 14.16. Other Display Library Technologies and Affiliated Services: Distribution by Types of Services Offered
  • Table 14.17. Other Display Library Technologies and Affiliated Service Providers: Distribution by Year of Establishment
  • Table 14.18. Other Display Library Technologies and Affiliated Service Providers: Distribution by Company Size
  • Table 14.19. Other Display Library Technologies and Affiliated Service Providers: Distribution by Type of Company
  • Table 14.20. Other Display Library Technologies and Affiliated Service Providers: Distribution by Location of Headquarters
  • Table 14.21. Biologics Discovered Using Phage Display Method: First Launch Year Timeline
  • Table 14.22. Biologics Discovered Using Phage Display Method: Distribution by Target Disease Indications and Therapeutic Area
  • Table 14.23. Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 14.24. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.25. Partnerships and Collaborations: Distribution by Focus Area (Type of Molecule)
  • Table 14.26. Partnerships and Collaborations: Distribution by Focus Area (Target Therapeutic Area)
  • Table 14.27. Partnerships and Collaborations: Distribution by Type of Partner
  • Table 14.28. Most Active Players: Distribution by Number of Partnerships
  • Table 14.29. Partnerships and Collaborations: Distribution by Geography
  • Table 14.30. Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Table 14.31. Publication Analysis: Cumulative Year-wise Trend, Since 2017
  • Table 14.32. Publication Analysis: Distribution by Focus Area
  • Table 14.33. Publication Analysis: Distribution by Type of Molecule
  • Table 14.34. Key Journals: Distribution by Number of Publications
  • Table 14.35. Patent Analysis: Distribution by Type of Patent
  • Table 14.36. Patent Analysis: Cumulative Distribution by Publication Year, Since 2017
  • Table 14.37. Patent Analysis: Distribution by Type of Patent and Publication Year
  • Table 14.38. Patent Analysis: Distribution by Geography
  • Table 14.39. Patent Analysis: Distribution by Jurisdiction
  • Table 14.40. Patent Analysis: Distribution by CPC Symbols
  • Table 14.41. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 14.42. Leading Industry Players: Distribution by Number of Patents
  • Table 14.43. Leading Players: Distribution by International Patents
  • Table 14.44. Patent Analysis: Distribution of Patents by Age
  • Table 14.45. Patent Analysis: Distribution of Patents by Geography, Since 2017
  • Table 14.46. Display Library Technologies: Patent Valuation
  • Table 14.47. Global Display Library Technologies and Affiliated Services Market (Focus on Hit Generation Services), Till 2035 (USD Million)
  • Table 14.48. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Display Library Technology (USD Million)
  • Table 14.49. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Molecule (USD Million)
  • Table 14.50. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Geography (USD Million)
  • Table 14.51. Display Library Technologies and Affiliated Services Market in North America, Till 2035 (USD Million)
  • Table 14.52. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Phage Display Technology (USD Million)
  • Table 14.53. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Yeast Display Technology (USD Million)
  • Table 14.54. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Display Technologies (USD Million)
  • Table 14.55. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Antibodies (USD Million)
  • Table 14.56. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Peptides (USD Million)
  • Table 14.57. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Molecules (USD Million)
  • Table 14.58. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Phage Display Technology (USD Million)
  • Table 14.59. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Yeast Display Technology (USD Million)
  • Table 14.60. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Display Technologies (USD Million)
  • Table 14.61. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Antibodies (USD Million)
  • Table 14.62. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Peptides (USD Million)
  • Table 14.63. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Molecules (USD Million)
  • Table 14.64. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Phage Display Technology (USD Million)
  • Table 14.65. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Yeast Display Technology (USD Million)
  • Table 14.66. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Display Technologies (USD Million)
  • Table 14.67. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Antibodies (USD Million)
  • Table 14.68. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Peptides (USD Million)
  • Table 14.69. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Molecules (USD Million)
目次
Product Code: RA100273

GLOBAL DRUG DISCOVERY PLATFORMS MARKET: OVERVIEW

As per Roots Analysis, the global drug discovery platforms market valued at USD 139 million in the current year is anticipated to grow at a CAGR of 13.4% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Display Library Technology

  • Phage Display
  • Yeast Display
  • Others

Type of Molecule

  • Antibodies
  • Peptides
  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific

GLOBAL DRUG DISCOVERY PLATFORMS MARKET: GROWTH AND TRENDS

Drug discovery has always been a time-consuming process. In fact, on average, it takes 10-15 years and investments worth USD 4-10 billion to commercially launch a drug. The process of drug discovery involves various steps including, target selection and validation, hit generation, lead optimization and characterization of protocols. Of these steps, hit (potential drug candidates against validated biological targets) generation is an extremely resource-intensive process. It is worth mentioning that on average approximately 18 months is spent generating hits against a validated target. In addition to this, there is an around 25% chance of failure in the hit generation to lead identification phase of drug discovery. In order to address these concerns, developers are shifting their focus from traditional techniques to the use of novel discovery platforms.

Drug Discovery Platforms Market - IMG1

Over the years, numerous methods and approaches have been established for generating viable therapeutic leads. These include hybridoma technology, B-cell cloning, transgenic animal-based techniques, in vitro display methods and cell surface display techniques involving mammalian, yeast, and bacterial cells. In modern medical research, display libraries have been effectively utilized to generate a range of novel therapeutics and present several advantages over traditional drug screening methods. These benefits include enabling large-scale, high-throughput screening, introducing greater diversity in identifying viable leads, and reducing the risk of immune responses to pharmacological candidates discovered through this approach. Gradually, display technologies have driven significant advancements in the drug discovery process. As a result, we anticipate that the market for drug discovery platforms will experience robust growth over the forecast period.

GLOBAL DRUG DISCOVERY PLATFORMS MARKET: KEY INSIGHTS

The report delves into the current state of global drug discovery platforms market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Several companies, based in different regions of the world, claim to have proprietary display library technologies and offer affiliated services for the discovery of various types of pharmacological molecules.
  • Phage display (~70%) is considered as one of the most successful display technologies; stakeholders are also investigating several other similar approaches, such as those based on yeast and mammalian cells.
  • Display technologies offer several advantages, including large scale production, direct access to sequence and the ease of screening a large diversity of clones.
  • Display libraries can be used for in vitro selection of antibodies on immobilized antigens and isolation of antibodies against poorly immunogenic targets.
  • Some players use multiple animal models for selection that can be manipulated under the control of the animal's immune system to generate drug candidates.
  • The growing interest in this field is evident from the rise in partnership activity; in fact, the maximum number of collaborations involving various types of display library technologies were inked in the past two years.
Drug Discovery Platforms Market - IMG2
  • Both established players, as well as start-ups, have forged multiple partnerships; most of these are licensing agreements (~45%) for the technologies that can be used in research and therapeutic purposes.
  • There has been a notable increase in published scientific literature related to the different types of in vitro display libraries and enabling technologies, and approaches describing their use in the discovery of drugs / therapies.
  • In the past two years, there has been an exponential increase in the number of publications, including research articles focused on display library technologies and their applications in drug discovery.
  • Various articles focus on in-vitro-display technologies and the use of large libraries for the isolation of vast range of molecules. Further, these technologies are primarily aimed at identifying promising lead candidates for use in therapeutic or diagnostic applications.
  • Apart from phage display, other display technologies, such as yeast display and cell surface display are also being investigated for the generation of various therapeutic molecules.
  • The intellectual property associated with display libraries has also witnessed a surge, as numerous patents (~30,000 patent applications) related to these technologies have been filed / granted to several organizations across the globe.
  • Despite the large number of patents that have been filed recently (and hence having a long remaining patent life), only 0.21% of the total patents have the highest relative valuation.
  • Specifically, the phage display approach has been widely used for the discovery of a number of approved drugs; in fact, HUMIRA(R), one of the best-selling biologics in the market, was discovered using the same technology.
  • The market is projected to grow at an annualized rate of ~13.4%; the forecasted opportunity is likely to be distributed across various display technologies, types of molecules, and key geographical regions.
Drug Discovery Platforms Market - IMG3

Example Players in the Drug Discovery Platforms Market

  • Abzena
  • Creative Biolabs
  • Distributed Bio (Subsidiary of Charles River)
  • ImmunoPrecise Antibodies
  • IONTAS
  • LakePharma
  • Leading Biology
  • Sino Biological
  • XOMA

PRIMARY RESEARCH OVERVIEW

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

  • Chief Scientific Officer / Founder and Chief Executive Officer / Founder, Company A
  • Chief Executive Officer / General Manager, Company B
  • President and Chief Executive Officer, Company C
  • General Manager, Company D

GLOBAL DRUG DISCOVERY PLATFORMS MARKET

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global drug discovery platforms market, focusing on key market segments, including [A] type of display library technology, [B] type of molecule and [C] key geographical regions.
  • Market Landscape: A comprehensive evaluation of the display library technologies and affiliated services market, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of company, [E] display library expertise, [F] type of molecules, [G] type and format of antibodies generated, [H] library size / complexity and [I] other services offered.
  • Company Profiles: In-depth profiles of companies offering display library technologies, focusing on [A] company overview, [B] proprietary technology and [C] recent developments and an informed future outlook.
  • Case Study: A detailed discussion of biologics discovered using phage display method along with analysis, based on various parameters, such as [A] first launch year, [B] target gene / antigen, [C] disease indication, [D] target therapeutic area and [E] revenues generated.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] focus area, [D] type of partner, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
  • Publication Analysis: A comprehensive analysis of close to 2,000 peer-reviewed scientific articles related to research on display libraries, based on [A] year of publication, [B] focus area, [C] type of molecule, [D] popular keywords and [E] key journals.
  • Patent Analysis: An in-depth analysis of patents filed / granted for display library technologies, based on various relevant parameters, such as [A] publication year, [B] geography, [C] CPC symbols, [D] emerging focus areas, [E] type of applicant, [F] leading industry players and [G] patent valuation analysis.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Display Library Technologies
  • 3.3. Types of Display Libraries
    • 3.3.1. In Vitro Display Technologies
      • 3.3.1.1. Phage Display
        • 3.3.1.1.1. Classification of Phage Display Libraries
        • 3.3.1.1.2. Applications of Phage Display Libraries
      • 3.3.1.2. Ribosomal Display Library
      • 3.3.1.3. mRNA Display Library
      • 3.3.1.4. cDNA Display Library
    • 3.3.2. Cell Surface Display Technologies
      • 3.3.2.1. Bacterial Display Library
      • 3.3.2.2. Yeast Display Library
      • 3.3.2.3. Mammalian Cell-based Display Libraries
  • 3.4. Applications of Display Libraries
  • 3.5. Future Perspectives

4. MARKET LANDSCAPE: LIBRARY-BASED DISPLAY TECHNOLOGIES AND SERVICES (FOCUS ON PHAGE DISPLAY)

  • 4.1. Chapter Overview
  • 4.2. Display Library Technologies and Affiliated Services (Focus on Phage Display): Overall Market Landscape
    • 4.2.1. Analysis by Type of Molecule Discovered
    • 4.2.2. Analysis by Type of Antibodies Generated
    • 4.2.3. Analysis by Type of Library
    • 4.2.4. Analysis by Library Size / Complexity
    • 4.2.5. Analysis by Source Organism
    • 4.2.6. Analysis by Types of Services Offered
  • 4.3. Display Library Technologies and Affiliated Services (Focus on Phage Display): Key Industry Players
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Type of Company
    • 4.3.4. Analysis by Location of Headquarters

5. MARKET LANDSCAPE: DISPLAY LIBRARY TECHNOLOGIES AND AFFILIATED SERVICES (FOCUS ON OTHER DISPLAY TECHNOLOGIES)

  • 5.1. Chapter Overview
  • 5.2. Display Library Technologies and Affiliated Services (Focus on Other Display Technologies): Overall Market Landscape
    • 5.2.1. Analysis by Type of Technology
    • 5.2.2. Analysis by Type of Molecule Discovered
    • 5.2.3. Analysis by Type of Antibodies Generated
    • 5.2.4. Analysis by Type of Library
    • 5.2.5. Analysis by Library Size / Complexity
    • 5.2.6. Analysis by Source Organism
    • 5.2.7. Analysis by Types of Services Offered
  • 5.3. Display Library Technologies and Affiliated Services (Focus on Other Display Technologies): Key Industry Players
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Type of Company
    • 5.3.4. Analysis by Location of Headquarters

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Abzena
    • 6.2.1. Company Overview
    • 6.2.2. Technology Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Creative Biolabs
    • 6.3.1. Company overview
    • 6.3.2. Technology Portfolio
    • 6.3.3. Service Portfolio
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. Distributed Bio (Subsidiary of Charles River)
    • 6.4.1. Company Overview
    • 6.4.2. Technology Portfolio
      • 6.4.2.1. Recent Developments and Future Outlook
  • 6.5. ImmunoPrecise Antibodies
    • 6.5.1. Company Overview
    • 6.5.2. Technology Portfolio
    • 6.5.3. Service Portfolio
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. IONTAS
    • 6.6.1. Company Overview
    • 6.6.2. Technology Portfolio
    • 6.6.3. Service Portfolio
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. LakePharma
    • 6.7.1. Company Overview
    • 6.7.2. Technology Portfolio
    • 6.7.3. Service Portfolio
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Leading Biology
    • 6.8.1. Company overview
    • 6.8.2. Technology Portfolio
    • 6.8.3. Service Portfolio
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. Sino Biological
    • 6.9.1. Company Overview
    • 6.9.2. Technology Portfolio
    • 6.9.3. Service Portfolio
    • 6.9.4. Recent Developments and Future Outlook
  • 6.10. XOMA
    • 6.10.1. Company Overview
    • 6.10.2. Technology Portfolio
    • 6.10.3. Recent Developments and Future Outlook

7. CASE STUDY: BIOLOGICS DISCOVERED USING PHAGE DISPLAY METHOD

  • 7.1. Chapter Overview
  • 7.2. Biologics Discovered Using the Phage Display Method
    • 7.2.1. Analysis by Year of Launch
    • 7.2.2. Analysis by Target Antigen / Gene
    • 7.2.3. Analysis by Target Disease Indication and Therapeutic Area
    • 7.2.4. Analysis by Revenues Generated (2020)
  • 7.3. Biologics Discovered Using Phage Display Method: Brief Profiles
    • 7.3.1. Humira(R) (Adalimumab)
      • 7.3.1.1. Drug Overview
      • 7.3.1.2. Discovery Process and Method
    • 7.3.2. Tremfya(R) (Guselkumab)
      • 7.3.2.1. Drug Overview
      • 7.3.2.2. Discovery Process and Method
    • 7.3.3. Takhzyro(R) (Lanadelumab)
      • 7.3.3.1. Drug Overview
      • 7.3.3.2. Discovery Process and Method
    • 7.3.4. Xyntha(R)
      • 7.3.4.1. Drug Overview
      • 7.3.4.2. Discovery Process and Method
    • 7.3.5. Portrazza(TM) (Necitumumab)
      • 7.3.5.1. Drug Overview
      • 7.3.5.2. Discovery Process and Method
  • 7.4. Concluding Remarks

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Display Library Technologies and Affiliated Services: Recent Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Focus of Partnership (Type of Molecule)
    • 8.3.4. Analysis by Focus of Partnership (Target Therapeutic Area)
    • 8.3.5. Analysis by Type of Partner
    • 8.3.6. Most Active Players: Analysis by Number of Partnerships
    • 8.3.7. Analysis by Geography
      • 8.3.7.1. Intercontinental and Intracontinental Agreements

9. PUBLICATION ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Analysis by Year of Publication
  • 9.4. Analysis by Focus Area (Type of Technology)
  • 9.5. Analysis by Focus Area (Type of Molecule)
  • 9.6. Word Cloud: Analysis of Study Titles
  • 9.7. Key Journals: Analysis by Number of Publications

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Display Library Technologies: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Geography
    • 10.3.3. Analysis by CPC Symbols
    • 10.3.4. Emerging Focus Areas (Word Cloud)
    • 10.3.5. Analysis by Type of Applicant
    • 10.3.6. Leading Players: Analysis by Number of Patents
    • 10.3.7. Leading Players: International Patents
    • 10.3.8. Display Library Technologies: Patent Valuation Analysis

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key assumptions and Forecast Methodology
  • 11.3. Global Display Library Technologies Market (Focus on Hit Generation Services), Till 2035
  • 11.4. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Display Library Technology
  • 11.5. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Type of Molecule
  • 11.6. Display Library Technologies and Affiliated Services Market, Till 2035: Distribution by Geography
    • 11.6.1. Display Library Technologies and Affiliated Services Market Opportunity in North America Across Key Market Segments, Till 2035
      • 11.6.1.1. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Distribution by Type of Technology
        • 11.6.1.1.1 Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Phage Display Technology
        • 11.6.1.1.2. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Yeast Display Technology
        • 11.6.1.1.3. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Display Technologies
      • 11.6.1.2. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Distribution by Type of Molecule
        • 11.6.1.2.1. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Antibodies
        • 11.6.1.2.2. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Peptides
        • 11.6.1.2.3. Display Library Technologies and Affiliated Services Market in North America, Till 2035: Share of Other Molecules
    • 11.6.2. Display Library Technologies and Affiliated Services Market Opportunity in Europe Across Key Market Segments, Till 2035
      • 11.6.2.1. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Distribution by Type of Technology
        • 11.6.2.1.1 Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Phage Display Technology
        • 11.6.2.1.2. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Yeast Display Technology
        • 11.6.2.1.3. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Display Technologies
      • 11.6.2.2. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Distribution by Type of Molecule
        • 11.6.2.2.1. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Antibodies
        • 11.6.2.2.2. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Peptides
        • 11.6.2.2.3. Display Library Technologies and Affiliated Services Market in Europe, Till 2035: Share of Other Molecules
    • 11.6.3. Display Library Technologies and Affiliated Services Market Opportunity in Asia-Pacific Across Key Market Segments, Till 2035
      • 11.6.3.1. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Distribution by Type of Technology
        • 11.6.3.1.1 Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Phage Display Technology
        • 11.6.3.1.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Yeast Display Technology
        • 11.6.3.1.3. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Display Technologies
      • 11.6.3.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Distribution by Type of Molecule
        • 11.6.3.2.1. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Antibodies
        • 11.6.3.2.2. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Peptides
        • 11.6.3.2.3. Display Library Technologies and Affiliated Services Market in Asia-Pacific, Till 2035: Share of Other Molecules

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. Company A
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: CSO / Founder and CEO / Founder
  • 13.3. Company B
    • 13.3.1. Company Snapshot
    • 13.3.2. Interview Transcript: CEO / General Manager
  • 13.4. Company C
    • 13.4.1. Company Snapshot
    • 13.4.2. Interview Transcript: President and CEO
  • 13.5. Company D
    • 13.5.1. Company Snapshot
    • 13.5.2. Interview Transcript: General Manager

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS